NY-MOTIVE-PARTNERS
12.7.2022 09:02:10 CEST | Business Wire | Press release
Motive Partners ("Motive"), a leading specialized private equity firm focused on financial technology, today announced the successful final close of its second flagship fund, Motive Capital Fund 2 (the "Fund"), with total capital commitments of $2.54 billion for the Fund and its affiliated co-investment vehicles.
The Fund employs the same investment strategy executed in Motive Partners' inaugural flagship fund. The Fund focuses on growth and buyout investments in software, investment and information services businesses located in North America and Europe. The Fund has already partnered with ten companies - InvestCloud, Insurify, Wilshire, Trumid, Motive Capital Corp II, CAIS, FNZ, Forge Global, BetaNXT and Backbase.
Commitments to the Fund were secured from a geographically diverse group of investors, including public and private pensions, sovereign wealth funds, foundations, financial institutions, institutional fund managers, family offices and high net worth individuals. Existing investors from the inaugural fund were joined by a significant group of new investors.
Rob Heyvaert, Founder & Managing Partner at Motive Partners , commented: "We are deeply grateful for the support from our existing investors and are delighted to welcome a roster of new partners to the Motive family - thank you for your trust. We will continue to be laser-focused on partnering transformational capital with world-class management teams."
During the fundraising period, Motive continued to invest behind its integrated approach, building out the Motive team to include over 180 Investors, Operators and Innovators.
Bob Brown, Founding Partner & Head of Investor Relations , commented: "We greatly appreciate the support of such an esteemed and diverse group of investors, and we take seriously the responsibility that our investors have bestowed upon us. We continue to invest into our distinct operating capabilities, allowing us to identify attractive investment opportunities and support our portfolio companies in the next stage of their growth."
About Motive Partners
Founded in 2016, Motive Partners is a specialist private equity firm with offices in North America and Europe, focused on backing, building, and buying technology companies that enable the financial economy. At the time of the final closing of the Fund, Motive Partners has over $5.5 billion in regulatory assets under management and has established an integrated team of over 180 Investors, Operators and Innovators. The firm focuses on growth equity and buyout investments in software, investment and information services companies in North America and Europe, serving five primary subsectors: Banking & Payments, Capital Markets, Data & Analytics, Wealth & Investment Management, and Insurance. Motive Partners is a privately held firm majority-owned by its partners, and brings differentiated expertise, connectivity, and capabilities to create long-term value in financial technology companies.
More information on Motive Partners can be found at www.motivepartners.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005158/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release
ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release
Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
